Meet Our Leadership
Founder & President
Sushil K. Mahata, Ph.D.
Dr. Mahata is Professor of Medicine at UC San Diego, Research Physiologist at the VA San Diego Healthcare System, and Founder and President of CgA Therapeuticals. A co-discoverer of catestatin (CST), his research spans cardiovascular, metabolic, inflammatory, and neurodegenerative diseases.
Read More
Chief Scientific Officer
Manjula Mahata, Ph.D.
Dr. Mahata leads CgA Therapeuticals' scientific and translational programs focused on the development of catestatin (CST)-based peptides and next-generation peptidomimetics.
Read More
Scientific Advisor
Gautam K Bandyopadhyay, Ph.D.
Dr. Gautam K. Bandyopadhyay is a metabolic scientist with extensive expertise in insulin signaling, glucose and lipid metabolism, and metabolic disease. His research has contributed to understanding the metabolic actions of catestatin (CST) in obesity, insulin resistance, and related metabolic disorders. At CgA Therapeuticals, he provides scientific expertise supporting the development of CST-based therapies for metabolic disease.
Read More
Principal Consultant
Subrata Das, Ph.D.
Dr. Das is a pharmaceutical scientist with extensive experience in drug development, formulation science, Chemistry, Manufacturing, and Controls (CMC), and translational development. At CgA Therapeuticals, he provides expertise in CMC, formulation development, sustained-release drug delivery, manufacturability, and translational strategy, supporting the advancement of CST, retro-inverso CST (RI-CST), and next-generation CST -based therapeutics toward clinical development.
Read More
Attorney
Cristina Rodriguez Rios
Ms. Rodriguez Rios has over fifteen years of experience in the areas of corporate law, finance, and international transactions. She has a broad-based corporate practice, which includes the provision of general counsel services for clients, international transactions, corporate formation and governance, mergers and acquisitions, real estate financing and commercial leasing, venture capital financing, antitrust compliance, telecommunications law and intellectual property licensing.
Read MoreCatestatin
Catestatin (CST) is a naturally occurring, 21-amino-acid bioactive peptide derived from the neuroendocrine secretory protein chromogranin A (CgA). Originally discovered as an endogenous inhibitor of nicotinic cholinergic-stimulated catecholamine release, CST has subsequently emerged as a multifunctional regulatory peptide with important actions in cardiovascular, metabolic, immune, gastrointestinal, and nervous-system physiology.
Read MorePatents & Intellectual Property
CgA Therapeuticals is building an intellectual property portfolio centered on catestatin (CST), next-generation CST-based peptides and peptidomimetics, Boolean implication network technologies, and related therapeutic and computational innovations.
The company has entered into an exclusive license agreement with The Regents of the University of California, represented by UC San Diego, covering defined patent rights for specified therapeutic technologies.
Read MoreTherapeutic Platform
CgA Therapeuticals is developing catestatin (CST) and next-generation CST-based peptides and peptidomimetics as potential therapeutics for diseases involving dysregulated neuroendocrine signaling, inflammation, metabolism, gastrointestinal function, cardiovascular homeostasis, and neurodegeneration.
Rather than acting through a single disease-associated pathway, CST influences multiple interconnected biological processes involved in maintaining physiological homeostasis, providing the scientific foundation for a platform-based therapeutic strategy across multiple areas of unmet medical need.
Read MoreFederal Research Support
CgA Therapeuticals' therapeutic programs are supported by a foundation of federally funded research investigating catestatin (CST), chromogranin A (CgA), aging, neurodegeneration, gastrointestinal dysfunction, metabolic disease, and related therapeutic applications. Current and selected prior awards relevant to the scientific development of the CST therapeutic platform are highlighted below.
Current Research Support
NIH/NIDDK SBIR Phase I
Peptide and Peptidomimetic Therapy for Gastroparesis
CgA Therapeuticals, Inc. | 2026–2027
Award No. 1R43DK148298-01 | Total Award: $350,195
Supports the preclinical development of CST and CST-based peptidomimetics as potential therapies for gastroparesis.